Bradley Neil Gaynes, MD, MPH, in summarizing the changes that have occurred in therapy for major depressive disorder (MDD) over the past several decades, reviews the more recent pharmacologic drugs added to the psychiatric treatment inventory, including nonstandard agents like ketamine, and also touches on other modes, specifically transcranial magnetic stimulation.
This accumulation of therapies, Dr Gaynes suggests, in turn feeds a constantly widening circumference of awareness regarding patient response, so that assessment of progress is based not just in the application of individual clinical points but also in the greater context of patients' lives, which includes more nuanced and far-reaching measures of success.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Major Depressive Disorder: The Importance of Patient-Centered Outcomes - Medscape - Oct 03, 2022.